Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
27 September 2023 - 11:40PM
Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage
biopharmaceutical company focused on developing and commercializing
viral immunotherapies to help patients fight cancer, today
announced the Company will present three posters at the Society for
Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place
November 3-5, 2023 in San Diego, CA and virtually.
Presentation details are as follows:
- CAN-2409 – Pancreatic Cancer
- Poster Presentation
Title: Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation
for Borderline Resectable or Locally Advanced Non-Metastatic
Pancreatic Adenocarcinoma (PDAC)
- Presenter: Garrett
Nichols, MD, MS, Chief Medical Officer, Candel Therapeutics
- Abstract Number:
653
- Session Date/Time:
Friday, November 3, 2023, 9 am – 7 pm PT
- Location: Exhibit
Halls A and B1 – San Diego Convention Center
- enLIGHTEN™ Discovery Platform
- Poster Presentation
Title: A novel viral immunotherapeutic targeting the
CD47/SIRPα axis demonstrates potent anti-tumor effects
- Presenter: Anne R.
Diers, PhD, Senior Director, Research, Candel Therapeutics
- Abstract Number:
1096
- Session Date/Time:
Saturday, November 4, 2023, 9 am – 8:30 pm PT
- Location: Exhibit
Halls A and B1 – San Diego Convention Center
- Poster Presentation
Title: Development of enLIGHTEN™ Alpha-201 herpes simplex
viral vectors encoding payloads targeting the tumor
microenvironment
- Presenter:
Francesca Barone, MD, PhD, Chief Scientific Officer, Candel
Therapeutics
- Abstract Number:
1348
- Session Date/Time:
Saturday, November 4, 2023, 9 am – 8:30 pm PT
- Location: Exhibit
Halls A and B1 – San Diego Convention Center
Further details from the presentations will be available
following the events on the Candel website at:
www.candeltx.com/media
About CAN-2409
CAN-2409, Candel’s most advanced viral immunotherapy candidate,
is an investigational off-the-shelf replication-defective
adenovirus designed to deliver the herpes simplex virus thymidine
kinase (HSV-tk) gene to a patient’s specific tumor and induce an
individualized, systemic immune response against the disease.
HSV-tk is an enzyme that locally converts orally administered
valacyclovir into a toxic metabolite that kills nearby cancer
cells. The intra-tumoral administration results in the release of
tumor-specific neoantigens in the microenvironment. At the same
time, the adenoviral serotype 5 capsid protein elicits a strong
pro-inflammatory signal in the tumor microenvironment. This is
designed to create the optimal conditions to induce an
individualized and specific CD8+ T cell mediated response against
the injected tumor and uninjected distant metastases for broad
anti-tumor activity. Because of its versatility, CAN-2409 has the
potential to treat a broad range of solid tumors. Encouraging
monotherapy activity as well as combination activity with standard
of care radiotherapy, surgery, chemotherapy, and ICI have
previously been shown in several preclinical and clinical settings.
Furthermore, more than 950 patients have been dosed with CAN-2409
with a favorable tolerability profile to date, supporting the
potential for combination with other therapeutic strategies without
inordinate concern of overlapping adverse events. Currently, Candel
is evaluating the effects of treatment with CAN-2409 in NSCLC,
borderline resectable pancreatic cancer, and localized,
non-metastatic prostate cancer in ongoing clinical trials. The U.S.
Food and Drug Administration granted Fast Track designation for
CAN-2409 plus valacyclovir in combination with pembrolizumab in
order to improve survival or delay progression in patients with
stage III/IV NSCLC who are resistant to first line anti-PD(L)1
therapy and who do not have activating molecular driver mutations
or have progressed on directed molecular therapy.
About the enLIGHTEN™ Discovery
Platform
Candel’s enLIGHTEN™ Discovery Platform is a systematic,
iterative HSV-based discovery platform leveraging human biology and
advanced analytics to create new viral immunotherapies for solid
tumors. In October 2022, the Company announced a discovery
collaboration with the University of Pennsylvania Center for
Cellular Immunotherapies to identify how viral immunotherapy could
enhance the efficacy of CAR-T cell therapy in solid tumors. The
enLIGHTEN™ Discovery Platform is designed to deconvolute the
complexity of the tumor microenvironment to identify druggable
properties that correlate with clinical outcomes. These discoveries
are translated into optimized multi-gene payloads of tumor
modulators that are tailored for specific indications, disease
stage, and rationally designed therapeutic combinations.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on
developing off-the-shelf viral immunotherapies that elicit an
individualized, systemic anti-tumor immune response to help
patients fight cancer. Candel’s engineered viruses are designed to
induce immunogenic cell death through direct viral-mediated
cytotoxicity in cancer cells, thus releasing tumor neo-antigens
while creating a pro-inflammatory microenvironment at the site of
injection. This leads to in-situ vaccination against the injected
tumor and uninjected distant metastases.
Candel has established two clinical stage viral immunotherapy
platforms based on novel, genetically modified adenovirus and
herpes simplex virus (HSV) gene constructs, respectively. CAN-2409
is the lead product candidate from the adenovirus platform and is
currently in ongoing clinical trials in NSCLC (phase 2), pancreatic
cancer (phase 2), and localized, non-metastatic prostate cancer
(phase 2 and phase 3). CAN-3110 is the lead product candidate from
the HSV platform and is currently in an ongoing
investigator-sponsored phase 1 clinical trial in recurrent
high-grade glioma. In addition, Candel’s enLIGHTEN™ Discovery
Platform is a systematic, iterative HSV-based discovery platform
leveraging human biology and advanced analytics to create new viral
immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements,” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, express or implied statements regarding the
timing and advancement of development programs, including the
timing and availability of additional data, the possibility to use
early biological readouts as predictor of clinical response and
expectations regarding the therapeutic benefit of its programs,
including the potential for CAN-2409 to extend patient survival.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the timing and
advancement of development programs; that final data from our
pre-clinical studies and completed clinical trials may differ
materially from reported interim data from ongoing studies and
trials; expectations regarding the therapeutic benefit of the
Company’s programs; the Company’s ability to efficiently discover
and develop product candidates; the Company’s ability to obtain and
maintain regulatory approval of product candidates; the Company’s
ability to maintain its intellectual property; the implementation
of the Company’s business model, and strategic plans for the
Company’s business and product candidates, and other risks
identified in the Company’s SEC filings, including the Company’s
most recent Quarterly Report on Form 10-Q filed with the SEC, and
subsequent filings with the SEC. The Company cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. The Company disclaims any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions, or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent the Company’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
Media ContactAljanae ReynoldsDirectorWheelhouse
Life Science Advisorsareynolds@wheelhouselsa.com
Investor ContactSylvia
WheelerPrincipalWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From Apr 2024 to May 2024
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From May 2023 to May 2024